Table II.

Supportive care and therapies delivered during support with VV ECMO.

Intervention/treatment	Total number = 152
IV Immunoglobulins	5 (3·3%)
Tocilizumab	8 (5·3%)
Plasmapheresis	14 (9·2%)
Steroids	91 (59·9%)
Haemostatic with tranexamic acid	14 (9·2%)
Blood product support
Red cell units (median and range)	7 (0–57)
Platelet units (median and range)	0 (0–10)
FFP units (median and range)	0 (0–48)
Cryoprecipitate units (median and range)	0 (0–12)
Fibrinogen (g; median and range)	0 (0–12)

VV ECMO, veno‐venous extracorporeal membrane oxygenation; FFP, fresh frozen plasma; IV, intravenous.

Supportive care and therapies were involving based on clinical studies and experience during the pandemic and not all available at the start of the study.